238 related articles for article (PubMed ID: 22454771)
41. Vascular extracellular matrix remodeling in cerebral aneurysms.
Bruno G; Todor R; Lewis I; Chyatte D
J Neurosurg; 1998 Sep; 89(3):431-40. PubMed ID: 9724118
[TBL] [Abstract][Full Text] [Related]
42. Cell surface complex of cathepsin B/annexin II tetramer in malignant progression.
Mai J; Waisman DM; Sloane BF
Biochim Biophys Acta; 2000 Mar; 1477(1-2):215-30. PubMed ID: 10708859
[TBL] [Abstract][Full Text] [Related]
43. TGF-beta1-Induced Expression of the Poor Prognosis SERPINE1/PAI-1 Gene Requires EGFR Signaling: A New Target for Anti-EGFR Therapy.
Samarakoon R; Higgins CE; Higgins SP; Higgins PJ
J Oncol; 2009; 2009():342391. PubMed ID: 19365582
[TBL] [Abstract][Full Text] [Related]
44. Concerted actions by MMPs, ADAMTS and serine proteases during remodeling of the cartilage callus into bone during osseointegration of hip implants.
Cassuto J; Folestad A; Göthlin J; Malchau H; Kärrholm J
Bone Rep; 2020 Dec; 13():100715. PubMed ID: 32995386
[TBL] [Abstract][Full Text] [Related]
45. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
46. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
47. Urokinase-type plasminogen activator stimulation of monocyte matrix metalloproteinase-1 production is mediated by plasmin-dependent signaling through annexin A2 and inhibited by inactive plasmin.
Zhang Y; Zhou ZH; Bugge TH; Wahl LM
J Immunol; 2007 Sep; 179(5):3297-304. PubMed ID: 17709546
[TBL] [Abstract][Full Text] [Related]
48. Matrix metalloproteinases and cellular fibrinolytic activity.
Lijnen HR
Biochemistry (Mosc); 2002 Jan; 67(1):92-8. PubMed ID: 11841344
[TBL] [Abstract][Full Text] [Related]
49. PAI-1 is a Critical Upstream Regulator of the TGF-beta1/EGF-Induced Invasive Phenotype in Mutant p53 Human Cutaneous Squamous Cell Carcinoma.
Wilkins-Port CE; Higgins CE; Freytag J; Higgins SP; Carlson JA; Higgins PJ
J Biomed Biotechnol; 2007; 2007(2):85208. PubMed ID: 17515947
[TBL] [Abstract][Full Text] [Related]
50. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
[TBL] [Abstract][Full Text] [Related]
51. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices.
Koolwijk P; Sidenius N; Peters E; Sier CF; Hanemaaijer R; Blasi F; van Hinsbergh VW
Blood; 2001 May; 97(10):3123-31. PubMed ID: 11342439
[TBL] [Abstract][Full Text] [Related]
52. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
53. PAI-1 in tissue fibrosis.
Ghosh AK; Vaughan DE
J Cell Physiol; 2012 Feb; 227(2):493-507. PubMed ID: 21465481
[TBL] [Abstract][Full Text] [Related]
54. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
Schmitt M; Jänicke F; Moniwa N; Chucholowski N; Pache L; Graeff H
Biol Chem Hoppe Seyler; 1992 Jul; 373(7):611-22. PubMed ID: 1515091
[TBL] [Abstract][Full Text] [Related]
55. Phenotypic overlap between MMP-13 and the plasminogen activation system during wound healing in mice.
Juncker-Jensen A; Lund LR
PLoS One; 2011 Feb; 6(2):e16954. PubMed ID: 21326869
[TBL] [Abstract][Full Text] [Related]
56. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
[TBL] [Abstract][Full Text] [Related]
57. Protease Nexin-1 affects the migration and invasion of C6 glioma cells through the regulation of urokinase Plasminogen Activator and Matrix Metalloproteinase-9/2.
Pagliara V; Adornetto A; Mammì M; Masullo M; Sarnataro D; Pietropaolo C; Arcone R
Biochim Biophys Acta; 2014 Nov; 1843(11):2631-44. PubMed ID: 25072751
[TBL] [Abstract][Full Text] [Related]
58. [Proteolysis directed by the extracellular matrix].
Hornebeck W; Emonard H; Maquart FX; Bellon G
J Soc Biol; 2003; 197(1):25-30. PubMed ID: 12868263
[TBL] [Abstract][Full Text] [Related]
59. Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems.
Krol J; Sato S; Rettenberger P; Assfalg-Machleidt I; Schmitt M; Magdolen V; Magdolen U
Biol Chem; 2003 Jul; 384(7):1085-96. PubMed ID: 12956425
[TBL] [Abstract][Full Text] [Related]
60. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair.
Soo C; Shaw WW; Zhang X; Longaker MT; Howard EW; Ting K
Plast Reconstr Surg; 2000 Feb; 105(2):638-47. PubMed ID: 10697171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
